Ask The Recruiter

Keros Therapeutics, Inc.

Leadership moves, last update 4 weeks ago

Pharma biotech · Headquarters United States

Everything we hold on Keros Therapeutics, Inc., newest first. Every line links to the filing or report it came from.

5 updates tracked
2 leadership changes
31 Dec 2023 tracked since
United States where
  1. 2026-07-22
    Headcount Not Stated Leadership moves

    Keros Therapeutics CFO Keith Regnante Resigns

    Keros Therapeutics CFO Keith Regnante resigns, with Annita Tanini stepping in as interim CFO. The change takes effect August 3, 2026.

    United States · Official Filing · SEC EDGAR

  2. 2026-02-26
    Headcount Not Stated Leadership moves

    Keros Therapeutics, Inc. 8-K filing (Item 5.02): officer or director change

    Keros Therapeutics adds a director to its board in Lexington, with no immediate change to executive roles disclosed.

    United States · Official Filing · SEC EDGAR

  3. 2025-12-31
    Pay Change Pay and benefits

    Keros Therapeutics, Inc.: $2,540,204 total compensation for the principal executive officer, fiscal year ended 2025-12-31

    Top-of-house pay is the anchor the rest of an employer's pay structure is set against, and it is the one compensation figure every US-listed company must publish on the same basis. Read it as a comparable, not as a salary band: it is a single officer's total, including equity awards valued under SEC rules, and it says nothing directly about what a given role pays.

    United States · Official Filing · SEC EDGAR (pay-versus-performance)

  4. 2024-12-31
    Pay Change Pay and benefits

    Keros Therapeutics, Inc.: $6,273,192 total compensation for the principal executive officer, fiscal year ended 2024-12-31

    Top-of-house pay is the anchor the rest of an employer's pay structure is set against, and it is the one compensation figure every US-listed company must publish on the same basis. Read it as a comparable, not as a salary band: it is a single officer's total, including equity awards valued under SEC rules, and it says nothing directly about what a given role pays.

    United States · Official Filing · SEC EDGAR (pay-versus-performance)

  5. 2023-12-31
    Pay Change Pay and benefits

    Keros Therapeutics, Inc.: $8,932,076 total compensation for the principal executive officer, fiscal year ended 2023-12-31

    Top-of-house pay is the anchor the rest of an employer's pay structure is set against, and it is the one compensation figure every US-listed company must publish on the same basis. Read it as a comparable, not as a salary band: it is a single officer's total, including equity awards valued under SEC rules, and it says nothing directly about what a given role pays.

    United States · Official Filing · SEC EDGAR (pay-versus-performance)

Cite this pageKeros Therapeutics, Inc.. Talent Intelligence Tracker, AskTheRecruiter.com. Accessed Aug 20, 2026. https://asktherecruiter.com/blog/talent-intelligence-tracker/company/keros-therapeutics/ Licensed CC BY 4.0; every record links to the document behind it.

The read-through on each line is our interpretation. The headline and figures come from the linked source. Data licensed CC BY 4.0. Back to the tracker